{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:40:01Z","timestamp":1747186801447,"version":"3.40.5"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004472","name":"Riksbankens Jubileumsfond","doi-asserted-by":"publisher","award":["P16\u20100112"],"award-info":[{"award-number":["P16\u20100112"]}],"id":[{"id":"10.13039\/501100004472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The cost\u2010effectiveness of the second\u2010generation direct\u2010acting antivirals (DAA) has received considerable attention; however, their effect on wider societal costs has remained relatively unexplored. The aim of this study was to investigate the effect the new drugs have on sick leave compared to older treatment paradigms. This retrospective study utilized Swedish registry data to identify three cohorts: (a) patients treated with ribavirin and\/or peginterferons (peg\u2010IFN) during 2005\u20102011; (b) patients treated with the first generation of DAAs and ribavirin and\/or peg\u2010IFN 2011\u20102013; and (c) patients treated with the new generation of DAAs 2014\u20102018. Individual\u2010level data on sick leave and early retirement were used to compare days away from work the year prior to the year following treatment initiation. A difference\u2010in\u2010difference model was estimated to test for differences between the cohorts adjusting for age and gender. Days away from work prior to treatment initiation was similar in the cohorts: 106, 85 and 94\u00a0days in cohorts 1 to 3. After treatment initiation, the number of days away from worked increased in cohort one and two to 150 and 140\u00a0days, while it remained similar in cohort three (88\u00a0days). The monetary value of the avoided sick leave was 7000\u201010\u00a0000 \u20ac. In conclusion, patients treated with second\u2010generation DAAs without peg\u2010IFN had fewer days of sick leave in the year following treatment initiation compared to older treatments. Some caution is advised when interpreting the absolute figures due to potential heterogeneity between cohorts as they were treated at different points in time.<\/jats:p>","DOI":"10.1111\/jvh.13398","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T13:22:54Z","timestamp":1600780974000},"page":"142-146","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced work absenteeism in patients with hepatitis C treated with second\u2010generation direct\u2010acting antivirals"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-8189","authenticated-orcid":false,"given":"Peter","family":"Lindgren","sequence":"first","affiliation":[{"name":"Department of Learning Informatics, Management and Ethics Karolinska Institutet Stockholm Sweden"},{"name":"The Swedish Institute for Health Economics Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"L\u00f6fvendahl","sequence":"additional","affiliation":[{"name":"The Swedish Institute for Health Economics Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Br\u00e5dvik","sequence":"additional","affiliation":[{"name":"The Swedish Institute for Health Economics Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-9724","authenticated-orcid":false,"given":"Ola","family":"Weiland","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases Karolinska Institutet Karolinska University Hospital Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2456-y"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1213651"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2018.1540929"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1373016"},{"volume-title":"The National Patient Register","year":"2019","author":"National Board of Health and Welfare","key":"e_1_2_6_6_1"},{"volume-title":"The National Prescribed Drugs Register","year":"2019","author":"National Board of Health and Welfare","key":"e_1_2_6_7_1"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12303"},{"volume-title":"MiDAS Sjukpenning och rehabiliteringspenning. (The MiDAS register. Sickness absence benefits)","year":"2019","author":"F\u00f6rs\u00e4kringskassan","key":"e_1_2_6_9_1"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/oso\/9780192631770.003.0005","volume-title":"Economic Evaluation in Health Care: Merging Theory With Practice","author":"Sculpher M","year":"2001"},{"volume-title":"Monthly Salaries by Sector 1992\u20132018","year":"2020","author":"Statistics Sweden","key":"e_1_2_6_11_1"},{"volume-title":"Ekonomifakta","year":"2020","author":"Svenskt N\u00e4ringsliv","key":"e_1_2_6_12_1"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1515\/9781400829828"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.003"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"volume-title":"F\u00f6r\u00e4ndringar inom socialf\u00f6rs\u00e4krings och bidragsomr\u00e5dena 1968\u201301\u201001\u20102019\u201309\u201001 [Changes to social insurance and benefits Jan 1st 1968\u2010Sep 1st 2019]","year":"2019","author":"F\u00f6rs\u00e4kringskassan","key":"e_1_2_6_17_1"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00864-8"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13398","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T09:35:46Z","timestamp":1723628146000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/jvh.13398"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13398","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2020,9,22]]},"assertion":[{"value":"2020-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}